Securities Registration: Employee Benefit Plan (s-8)
October 12 2017 - 7:55AM
Edgar (US Regulatory)
As filed with the Securities and Exchange
Commission on October 12, 2017
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
46-0524102
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
235 Walnut Street, Suite 6
Framingham, MA 01702
(Address of Principal Executive Offices
and Zip Code)
ARCH THERAPEUTICS, INC. 2013 STOCK INCENTIVE
PLAN
(Full title of the plan)
Terrence W. Norchi
Chief Executive Officer
Arch Therapeutics, Inc.
235 Walnut Street, Suite 6
Framingham, MA 01702
(Name and address of agent for service)
(617) 431-2313
(Telephone number, including area code,
of agent for service)
Copy to
:
John D. Hogoboom, Esq.
Lowenstein Sandler LLP
65 Livingston Avenue
Roseland, New Jersey 07068
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated
filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large
accelerated filer
¨
|
|
Accelerated
filer
x
|
Non-accelerated
filer
¨
|
|
Smaller
reporting company
¨
|
(Do not
check if a smaller reporting company)
|
|
Emerging
Growth company
¨
|
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
CALCULATION OF REGISTRATION FEE
Title
of Securities
to be Registered
|
|
Amount
to be
Registered (1)
|
|
|
Proposed
Maximum
Offering Price
Per Share (2)
|
|
|
Proposed
Maximum
Aggregate
Offering Price (2)
|
|
|
Amount
of
Registration Fee
|
|
Common
Stock, par value $0.001 per share
|
|
|
3,000,000
|
|
|
$
|
0.78
|
|
|
$
|
2,340,000
|
|
|
$
|
291.33
|
|
|
(1)
|
Represents the number of additional shares of common stock, par value $0.001 per share (“
Common Stock
”),
of Arch Therapeutics, Inc. (the “
Company
” or “
Registrant
”), that may be issued in connection
with the Arch Therapeutics, Inc. 2013 Stock Incentive Plan (the “
Plan
”). In addition, pursuant to Rule 416(a)
under the Securities Act of 1933, as amended (the “
Securities Act
”), this Registration Statement also registers
such additional shares of Common Stock as may be offered or issued under the Plan to prevent dilution from stock splits, stock
dividends, or similar transactions.
|
|
(2)
|
Estimated solely for purposes of calculating the amount of the registration fee, pursuant to Rules 457(c) and 457(h)(1) of
the Securities Act, the proposed maximum offering price per share and the proposed maximum aggregate offering price for the shares
have been determined on the basis of the average of the high and low prices of the registrant’s Common Stock reported on
the OTCQB tier of the OTC Marketplace on October 10, 2017, which were $0.77 and $0.79, respectively.
|
STATEMENT REGARDING REGISTRATION OF ADDITIONAL
SECURITIES PURSUANT TO GENERAL INSTRUCTION E
This registration statement on Form S-8 (this “
Registration
Statement
”) is filed by Arch Therapeutics, Inc. (the “
Company
” or “
Registrant
”),
to register an additional 3,000,000 shares of the Registrant’s common stock, par value $0.001 per share (the “
Common
Stock
”), which may be issued under the Arch Therapeutics, Inc. 2013 Stock Incentive Plan (the “
Plan
”).
Pursuant to Section 3(a) of the Plan, on the first business
day of each fiscal year commencing with the fiscal year beginning October 1, 2013, the number of shares of Common Stock issuable
under the Plan for all awards except for incentive stock option awards automatically increase by an amount equal to the lesser
of (A) 3,000,000 shares, (B) four (4) percent of the number of shares outstanding on the last day of the immediately preceding
fiscal year of the Company, or (C) such lesser number of shares as determined by the Company’s Board of Directors (the “
Annual
Increase
”). Since the number of shares of Common Stock outstanding as of September 30, 2017, the last day of the immediately
preceding fiscal year, was 153,692,857 shares, the Annual Increase for the fiscal year commencing October 1, 2017 is 3,000,000
shares of Common Stock.
Pursuant to the Registration Statements on Form S-8 filed by
the Registrant on January 23, 2014 (Registration No. 333-193516), December 23, 2014 (Registration No. 333-201229), October 7, 2015
(Registration No. 333-207314) and November 4, 2016 (Registration No. 333-214429), respectively (collectively, the “
Prior
Registration Statements
”), the Registrant previously registered an aggregate of 19,676,958 shares of Common Stock. The
additional shares of Common Stock being registered by this Registration Statement are of the same class as those securities registered
on the Prior Registration Statements and represent an increase in the total shares of Common Stock that have been registered for
sale under the Securities Act from 19,676,958 to 22,676,958. The contents of the Prior Registration Statements, together with all
exhibits filed therewith or incorporated therein by reference to the extent not otherwise amended or superseded by the contents
hereof or otherwise, are incorporated herein by reference in accordance with General Instruction E to Form S-8.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a)
PROSPECTUS
The documents containing the information specified in Part I
of this Registration Statement have been or will be sent or given to participating employees as specified in Rule 428(b)(1) of
the Securities Act in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “
SEC
”).
Such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus
supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this Registration
Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the
requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT
Item 3. Incorporation of Certain Documents by Reference.
The following documents, filed with the SEC by the Company,
are incorporated by reference into this Registration Statement:
|
(a)
|
the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016 filed with the SEC on December
5, 2016, pursuant to the Securities Exchange Act of 1934, as amended (the “
Exchange Act
”);
|
|
(b)
|
the Company’s Quarterly Reports on Form 10-Q for the quarters ended December 31, 2016, March 31, 2017, and June 30, 2017,
filed with the SEC on February 1, 2017, May 2, 2017, and July 27, 2017, respectively,
|
|
(c)
|
the Company’s Current Reports on Form 8-K, filed with the SEC on September 29, 2016, October 31, 2016, February 2, 2017,
February 16, 2017, February 21, 2017, June 6, 2017, July 25, 2017 and September 12, 2017, respectively, in each case pursuant to
the Exchange Act; and
|
|
(d)
|
the description of the Company’s Common Stock, which is contained in the Company’s Registration Statement on Form
8-A, filed with the SEC on June 26, 2013, together with any amendment or report filed with the SEC for the purpose of updating
this description.
|
In addition, all documents filed by the Company with the SEC
pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act subsequent to the date of this Registration Statement and
prior to the filing of a post-effective amendment to this Registration Statement which indicates that all the securities offered
hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference
in this Registration Statement and to be a part hereof from the date of the filing of such documents with the SEC;
provided,
however
, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission
shall not be deemed incorporated by reference in this Registration Statement, including any portion of any future annual or quarterly
report to stockholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under
such provisions. Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded
for purposes hereof to the extent that a statement contained herein (or in any other subsequently filed document which also is
incorporated by reference herein) modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed
to constitute a part hereof except as so modified or superseded.
Item 8. Exhibits.
The Exhibits to this Registration Statement are listed in the
Index to Exhibits and are incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933,
the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Framingham, State of Massachusetts, on October 12, 2017.
|
Arch Therapeutics, Inc.
|
|
|
|
/s/ Terrence W. Norchi, MD
|
|
Terrence W. Norchi, MD
|
|
President and Chief Executive Officer
|
SIGNATURES AND POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS
, that we, the undersigned
officers and directors of Arch Therapeutics, Inc., a Nevada corporation (the “
Company
”), do hereby constitute
and appoint each of Terrence W. Norchi and Richard E. Davis as his or her true and lawful attorney-in-fact and agent, with full
power of substitution and re-substitution, for him or her and in his or her name, place, and stead, in any and all capacities,
to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith)
to this Registration Statement and any subsequent registration statement filed by the registrant pursuant to Rule 462(b) of the
Securities Act of 1933, as amended, which relates to this Registration Statement, and to file the same, with all exhibits thereto,
and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact
and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each
said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933,
this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Terrence W. Norchi, MD
|
|
President, Chief Executive Officer, and Director
|
|
October 12, 2017
|
Terrence W. Norchi, MD
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Richard E. Davis
|
|
Chief Financial Officer
|
|
October 12, 2017
|
Richard E. Davis
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Avtar Dhillon, MD
|
|
Director
|
|
October 12, 2017
|
Avtar Dhillon, MD
|
|
|
|
|
|
|
|
|
|
/s/ James R. Sulat
|
|
Director
|
|
October 12, 2017
|
James R. Sulat
|
|
|
|
|
INDEX TO EXHIBITS
Exhibit No.
|
|
Description of Exhibit
|
4.1
|
|
Restated Articles of Incorporation of Arch Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Annual Report on Form 10-K filed by the Company with the SEC on December 12, 2014)(File Number 000-54986)
|
|
|
|
4.2
|
|
Amended and Restated Bylaws of Arch Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Company with the SEC on June 24, 2013)(File Number 333-178883)
|
|
|
|
10.1
|
|
Arch Therapeutics, Inc. 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company with the SEC on June 24, 2013)(File Number 333-178883)
|
|
|
|
10.2
|
|
Form of Stock Option Award Agreement under Arch Therapeutics, Inc. 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to the Quarterly Report on Form 10-Q filed by the Company with the SEC on August 14, 2013)(File Number 000-54986)
|
|
|
|
10.3
|
|
Form of Restricted Stock Unit Award Agreement under Arch Therapeutics, Inc. 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.14 to the Quarterly Report on Form 10-Q filed by the Company with the SEC on August 14, 2013)(File Number 000-54986)
|
|
|
|
10.4
|
|
Form of Restricted Stock Bonus Award Agreement under Arch Therapeutics, Inc. 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.15 to the Quarterly Report on Form 10-Q filed by the Company with the SEC on August 14, 2013)(File Number 000-54986)
|
|
|
|
5.1*
|
|
Opinion of McDonald Carano LLP.
|
|
|
|
23.1*
|
|
Consent of McDonald Carano LLP (included in Exhibit 5.1 hereto).
|
|
|
|
23.2*
|
|
Consent of Moody, Famiglietti & Andronico, LLP.
|
|
|
|
24.1*
|
|
Power of Attorney (included on the signature page of this Registration Statement).
|
* Filed herewith.
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Sep 2023 to Sep 2024